GAVI Alliance aims to immunize 30 million girls against HPV

The GAVI Alliance wants to immunize 30 million girls worldwide with HPV vaccines by 2020. Pilot projects in select countries--mainly in sub-Saharan Africa--will roll out next year. GAVI is working with Merck ($MRK) and GlaxoSmithKline ($GSK) to nail down the most affordable prices for HPV vaccines. In 2011, Merck said it would provide the vaccine at $5 per dose, a 64% reduction in the current lowest public price. The FDA licenses two HPV vaccines in the United States: Merck's Gardasil and GSK's Cervarix. Jabs will go to girls ages 9 to 13. Release

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.